StockNews.AI
MCRB
StockNews.AI
118 days

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

1. Seres will host a call on May 7 for Q1 2025 results. 2. SER-155 receives Breakthrough Therapy designation for bloodstream infection reduction. 3. Company's pipeline targets multiple vulnerable patient populations for therapies. 4. VOWST™ was the first FDA-approved microbiome therapeutic, enhancing credibility.

Earnings
+9.8%Current Return
VS
+3.5%S&P 500
$8.1604/23 07:06 AM EDTEvent Start
$8.9604/24 02:02 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Bullish?

The positive developments around SER-155 may increase investor confidence and interest. Historical parallels include stock reactions to positive clinical trial announcements.

How important is it?

The announcement of a significant therapy and a financial results call likely attract attention. The company's focus on innovative treatments supports future growth potential.

Why Short Term?

Quarterly results and updates can lead to immediate market reactions. Similar past events have resulted in quick spikes or declines in stock prices.

Related Companies

NESTREGNAMGN
April 23, 2025 07:00 ET  | Source: Seres Therapeutics, Inc. CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the “Investors and News” section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours after the event and will be archived for approximately 21 days. About Seres TherapeuticsSeres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com. Investor and Media Contact:  IR@serestherapeutics.com Carlo Tanzi, Ph.D.Kendall Investor Relationsctanzi@kendallir.com

Related News